These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 15996946)

  • 1. Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice.
    Wu KL; van Wieringen W; Vellenga E; Zweegman S; Lokhorst HM; Sonneveld P
    Haematologica; 2005 Jul; 90(7):996-7. PubMed ID: 15996946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
    Berenson JR; Jagannath S; Barlogie B; Siegel DT; Alexanian R; Richardson PG; Irwin D; Alsina M; Rajkumar SV; Srkalovic G; Singhal S; Limentani S; Niesvizky R; Esseltine DL; Trehu E; Schenkein DP; Anderson K
    Cancer; 2005 Nov; 104(10):2141-8. PubMed ID: 16206291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
    Wolf J; Richardson PG; Schuster M; LeBlanc A; Walters IB; Battleman DS
    Clin Adv Hematol Oncol; 2008 Oct; 6(10):755-60. PubMed ID: 18997666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of bortezomib (velcade) in the treatment of relapsed multiple mye.
    Warzocha K; Kraj M; Pogłód R; Sokołowska U
    Acta Pol Pharm; 2006; 63(5):452-5. PubMed ID: 17357614
    [No Abstract]   [Full Text] [Related]  

  • 5. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
    Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin DH; Rajkumar SV; Srkalovic G; Alsina M; Anderson KC
    Cancer; 2006 Mar; 106(6):1316-9. PubMed ID: 16470606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
    Richardson P; Jagannath S; Colson K
    Clin Adv Hematol Oncol; 2006 May; 4(5):1; discussion 8; suppl 13. PubMed ID: 16830422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Spigel DR; Barton J; Farley C; Schreeder M; Hon J; Greco FA
    Cancer; 2008 Aug; 113(4):765-71. PubMed ID: 18543319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
    Jagannath S; Barlogie B; Berenson JR; Siegel DS; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Esseltine DL; Anderson KC
    Br J Haematol; 2008 Nov; 143(4):537-40. PubMed ID: 18783399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
    Vogl DT; Stadtmauer EA; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Facon T; Harousseau JL; Boral A; Neuwirth R; Anderson KC
    Br J Haematol; 2009 Nov; 147(4):531-4. PubMed ID: 19725827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J; Cibeira MT; Rosiñol L
    Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
    Zangari M; Guerrero J; Cavallo F; Prasad HK; Esseltine D; Fink L
    Haematologica; 2008 Jun; 93(6):953-4. PubMed ID: 18515882
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and efficacy results from an international expanded access programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients.
    Quach H; Horvath N; Cannell P; Mikhael JR; Butcher BE; Prince HM
    Intern Med J; 2009 May; 39(5):290-5. PubMed ID: 19371392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.
    Dawson MA; Opat SS; Taouk Y; Donovan M; Zammit M; Monaghan K; Horvath N; Roberts AW; Prince HM; Hertzberg M; McLean CA; Spencer A
    Clin Cancer Res; 2009 Jan; 15(2):714-22. PubMed ID: 19147779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib data show improved survival in patients with relapsed multiple myeloma.
    Oncology (Williston Park); 2004 Aug; 18(9):1199, 1201. PubMed ID: 15471202
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
    Richardson P
    Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
    [No Abstract]   [Full Text] [Related]  

  • 16. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
    Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K
    Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
    Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; San Miguel JF; Cavenagh JD; Anderson KC
    Br J Haematol; 2007 Jun; 137(5):429-35. PubMed ID: 17451408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
    Bruno B; Patriarca F; Sorasio R; Mattei D; Montefusco V; Peccatori J; Bonifazi F; Petrucci MT; Milone G; Guidi S; Giaccone L; Rotta M; Fanin R; Boccadoro M; Corradini P;
    Haematologica; 2006 Jun; 91(6):837-9. PubMed ID: 16769588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.
    Hrusovsky I; Emmerich B; von Rohr A; Voegeli J; Taverna C; Olie RA; Pliskat H; Frohn C; Hess G
    Oncology; 2010; 79(3-4):247-54. PubMed ID: 21372599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
    Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P
    Oncology; 2006; 70(6):474-82. PubMed ID: 17283449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.